Tivantinib and Regorafenib for the Treatment of Liver Cancer

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.